Antonio Vazquez-Diaz
Neurology with Special Qualifications in Child Neurology · Orlando, FLNPI 1578613022
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,294 of the $4,794 with a category attached, or 89.6%. It is spread thinly across 33 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,187 and has fallen 77.3% since, to $270 in 2025.
Across 170 payments — averaging $28.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$863
- Neuropace, Inc.$460
- Sunovion Pharmaceuticals Inc.$448
- UCB, Inc.$350
- Biomarin Pharmaceutical Inc.$268
- SK Life Science, Inc.$228
- plus $2K from 27 others
What the payments were for
- Speaking & faculty fees$50010%
- Food & beverage$4,29490%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 27 | $863 |
| Neuropace, Inc. | 4 | $460 |
| Sunovion Pharmaceuticals Inc. | 26 | $448 |
| UCB, Inc. | 15 | $350 |
| Biomarin Pharmaceutical Inc. | 5 | $268 |
| SK Life Science, Inc. | 7 | $228 |
| Neurelis, Inc. | 10 | $201 |
| Livanova USA, Inc. | 2 | $193 |
| Jazz Pharmaceuticals Inc. | 8 | $185 |
| Sumitomo Pharma America, Inc. | 3 | $161 |
| Aquestive Therapeutics, Inc. | 7 | $153 |
| Eisai Inc. | 7 | $143 |
| Ipsen Biopharmaceuticals, Inc | 1 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $110 |
| Corium, LLC | 5 | $88 |
| AbbVie(2 entities) | 4 | $81 |
| Biocodex, Inc. | 1 | $80 |
| Acadia Pharmaceuticals Inc | 3 | $75 |
| Travere Therapeutics, Inc. | 3 | $69 |
| Immedica Pharma US, Inc. | 3 | $67 |
| Shire North American Group Inc | 3 | $58 |
| Ironshore Pharmaceuticals Inc. | 3 | $55 |
| Novartis | 3 | $54 |
| Greenwich Biosciences, Inc. | 3 | $53 |
| Catalyst Pharmaceuticals, Inc. | 2 | $52 |
| Azurity Pharmaceuticals, Inc. | 2 | $48 |
| Tris Pharma Inc | 2 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Amneal Pharmaceuticals LLC | 1 | $19 |
| NS Pharma, Inc. | 1 | $18 |
| Neurocrine Biosciences, Inc. | 1 | $15 |
| PTC Therapeutics, Inc. | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,794 in reported general payments places this provider in the 55th percentile of 137 neurology with special qualifications in child neurology providers in Florida.
See all neurology with special qualifications in child neurology providers in Florida →
Other neurology with special qualifications in child neurology in Orlando
- Omer Abdul HamidOrlando$283K
- Ngoc Minh leOrlando$19K
- Vikram PrakashOrlando$15K
- Ki-Hyeong LeeOrlando$15K
- Sheila Ramos MartinezOrlando$8K
- Anthony GiordanoOrlando$7K
- Murtuza KothawalaOrlando$5K
- Carl BarrOrlando$5K
- Dina DahanOrlando$5K
- Paul WinnerWest Palm Beach$624K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.